Navigation Links
Cepheid Schedules 2013 Fourth Quarter And Full Year Financial Results Announcement And Webcast
Date:1/9/2014

SUNNYVALE, Calif., Jan. 9, 2014 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced that it will report financial results for its 2013 fourth quarter and full year ended December 31, 2013 on Thursday, January 30, 2014, after the close of the market.

The Company will host a management presentation at 2 p.m. Pacific Time on Thursday, January 30, 2014, to discuss the results.  To access the live webcast, please visit Cepheid's website at http://ir.cepheid.com at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software.  A replay of the webcast will be available shortly following the call and will remain available for at least 90 days.

About CepheidBased in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests.  By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases.  Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit http://www.cepheid.com.CONTACTS: For Media Inquiries:For Investor Inquiries:Jared Tipton

Jacquie Ross, CFACepheid Corporate Communications

Cepheid Investor RelationsTel: (408) 400 8377

Tel: (408) 400 8329communications@cepheid.com

investor.relations@cepheid.com


'/>"/>
SOURCE Cepheid
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Welcomes Senior Vice President of Human Resources
2. Cepheid Reports Fourth Quarter and Full Year 2011 Results
3. Cepheid to Webcast Upcoming Financial Presentations
4. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
5. Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year
6. Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae
7. Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
8. Cepheid Reports 2012 Second Quarter Results
9. Cepheid Announces Board of Directors Changes
10. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
11. Cepheid Reports 2013 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017  VWR Corporation (NASDAQ: VWR), the leading global ... production customers, today reported its financial results for the fourth ... Highlights: 4Q16 record quarterly net sales ... an organic basis. 4Q16 EMEA-APAC ... basis, while the Americas net sales increased 2.5%, or down ...
(Date:2/23/2017)... Feb. 23, 2017 ... except per share data, unaudited)Three Months Ended December 31,Twelve ... Revenue $       ... 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  756025%297303(2)%Vimizim ...
(Date:2/23/2017)... SAN JOSE, Calif. , Feb. 23, 2017 ... an exclusive license for two key immunotherapy technologies ... The first technology provides a method to monitor ... therapy such as PD-L1 and CTLA-4.  The second ... detect if a patient is likely to have ...
(Date:2/23/2017)...  Imanis Life Sciences announced today the launch ... viruses for virotherapy research. These viruses are licensed ... vaccinia virus-based technology platform for research use. ... partnership with Genelux to offer researchers, for the ... in research," said Dr. Kah Whye Peng ...
Breaking Biology Technology:
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
(Date:1/24/2017)... 24, 2017 Biopharm Reports has carried ... use of nuclear magnetic resonance spectroscopy (NMR). This ... profiled current practices, developments, trends and end-user plans ... growth and opportunities. These areas include growth in ... needs and innovation requirements, hyphenated NMR techniques, main ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017 ... enhancing user experience and security for consumer electronics, ... next-generation payment processing systems and cybersecurity solutions, today ... banks, enterprises and financial institutions worldwide to bolster ... of the end-to-end secure user authentication platforms they ...
Breaking Biology News(10 mins):